This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Neoantigens: promising targets for cancer therapy
Signal Transduction and Targeted Therapy Open Access 06 January 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original articles
Hsiue, E. H. C. et al. Targeting a neoantigen derived from a common TP53 mutation. Science 371, eabc8697 (2021)
Douglass, J. et al. Bispecific antibodies targeting mutant RAS neoantigens. Sci. Immunol. 6, eabd5515 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
O’Leary, K. Bispecifics target cancers’ most wanted. Nat Rev Cancer 21, 279 (2021). https://doi.org/10.1038/s41568-021-00354-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41568-021-00354-0
This article is cited by
-
Neoantigens: promising targets for cancer therapy
Signal Transduction and Targeted Therapy (2023)